Ireland· IE-PA-PA0822/208/001
Vinblastine Sulfate 1mg/ml Solution for Injection or Infusion
A vinblastine product containing vinblastine sulfate, registered in Ireland by Pfizer Healthcare Ireland Unlimited Company. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Vinblastine is registered in 14 of 19 countries.
Countries holding a registration under ATC L01CA01 (vinblastine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Vinblastine · ATC L01CA01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vinblastine costs, country by country.
Normalised to the WHO defined daily dose (11.61 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vinblastine · price per daily dose (11.61 mg)
USD · FX 28 Sept 2026
- CH Switzerland$56.28
The record
At a glance
HPRA (Ireland)- Active substance
- VINBLASTINE SULFATE
- Manufacturer
- Pfizer Healthcare Ireland Unlimited Company
- Country
- Ireland (IE)
- ATC code
- L01CA01
- ATC class
- Vinblastine
- Defined daily dose
- 11.61 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA0822/208/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
416 interactions on record for vinblastine.
Graded by severity as the source publishes them — 61 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vinblastine · interactions on record
416 records
- 61 severe
- 303 moderate
- 24 minor
- 28 info
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- KetoconazoleH02CA03severe
- ErythromycinJ01FA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vinblastine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomVelbe 10mg powder for solution for injection vialsEli Lilly and Company Ltd
- GermanyVinblastin StadaStadapharm Gmbh
- CanadaVINBLASTINE SULFATE INJECTIONPFIZER CANADA ULC
- NorwayVelbeSTADA Nordic Aps
- FinlandVelbeSTADA Nordic ApS
- NetherlandsVinblastinesulfaat 1 mg/ml PCH, oplossing voor injectiePharmachemie B.V.
- SwedenVelbe 10 mg Pulver till injektionsvätska, lösningSTADA Nordic ApS
- BelgiumVinblastine Teva 1 mg/mlTeva
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Velbe
- Belgium · Vinblastine Teva
- Czechia · Vinblastin Teva
- Germany · Vinblastin Stada, Vinblastinsulfat Teva
- Denmark · Velbe
- Estonia · Vinblastine Teva
- Spain · Vinblastina Stada
- Finland · Velbe
- France · Velbe
- United Kingdom (Northern Ireland) · Vinblastine Sulfate Hospira Uk
- Italy · Velbe
- Lithuania · Vinblastine Teva
- Luxembourg · Vinblastine Teva
- Latvia · Vinblastine Teva
- Malta · Vinblastine Sulfate Pfizer Hellas
- Netherlands · Vinblastinesulfaat Pch
- Norway · Velbe
- Portugal · Solblastin
- Romania · Vinblastină Teva
- Sweden · Velbe
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f21e5122-aad2-4581-abf7-2806b9fcdb03 GET /v1/drugs/f21e5122-aad2-4581-abf7-2806b9fcdb03?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection/infusion",
"routes": [
"Not Currently Available"
],
"source": "hpra",
"atc_all": [
"L01CA",
"L01CA01"
],
"strength": null,
"pa_number": "PA0822/208/001",
"substances": [
"VINBLASTINE SULFATE"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "15/10/1990",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about vinblastine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.